Aptar Pharma and COVIRIX Medical have entered a technical collaboration under a Letter of Intent. They aim to develop inhalable antiviral treatments for pandemic-potential respiratory viruses. The collaboration will focus on a feasibility study for COVIRIX’s antiviral compound. Both companies will adapt Aptar’s proprietary dry powder inhalation (DPI) platform for this project.
The project intends to explore an integrated finished product for several viruses. These include COVID-19, seasonal influenza, avian influenza, and RSV. By targeting the respiratory tract directly, these inhalable antiviral treatments aim for high local efficacy. Furthermore, this method helps minimize systemic side effects for patients worldwide.
Advancing Respiratory Medicine Through Innovation
Aptar Pharma will utilize its advanced Orbital technology for drug delivery. This novel device delivers high payload powder drug formulations directly to the lungs. Meanwhile, COVIRIX Medical, based in Australia, offers patented broad-spectrum antiviral compounds. Thus, the partnership is addressing some of the most pressing global challenges.
The partnership will also utilize specific capabilities from Nanopharm, which is a company of Aptar Pharma. Nanopharm provides formulation development capabilities, as well as helping customers overcome complex regulatory challenges. This will enable the customer to develop inhalable antiviral treatments. Both teams remain committed to improving lives through scientific engineering.
Moreover, COVIRIX Medical reports positive virology results against key pandemic-potential viruses. The company is dedicated to repurposing and developing therapeutics for epidemic respiratory diseases. This partnership will enable access to critical delivery technology and business relationships. The two companies are excited about these innovative pulmonary therapies.
Jonathan Mulpas, Aptar Pharma’s Director of Business Development, shared his pride in the project. He noted the potential to help patients across the world.
“Covirix’s portfolio of antivirals addresses several global challenges, and Aptar Pharma is proud to actively support and accelerate the development of a product that has the potential to help patients worldwide.”
Dr. Kumud Dhital, Director and CEO of COVIRIX Medical, also emphasized the benefits of the deal. He believes it accelerates the path to market for an antiviral solution.
“This collaboration provides access to critical delivery technology and commercial relationships. It accelerates our path to market for a much-needed antiviral solution, creating a win-win for both companies and global public health.”
The feasibility work does not yet guarantee the commercialization of any product. However, both companies remain focused on advancing these important medical treatments.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
